PCRX Pacira Biosciences Inc.

American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.

American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.

SCHAUMBERG, Ill. and TAMPA, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- The American Society of Anesthesiologists (ASA) today announced Pacira BioSciences, Inc. (Nasdaq: PCRX) has joined ASA’s Industry Supporter Program to support the Society’s more than 56,000 physician anesthesiologist members to improve patient care and reduce reliance on opioids for the treatment of postsurgical or chronic pain.

“We are delighted to establish this collaboration with Pacira, which we believe represents an excellent opportunity to advance education and innovation for our members,” said ASA President Michael Champeau, M.D., FAAP, FASA. “Pacira and the ASA share a mutual commitment toward best-in-class pain medicine and optimizing patient outcomes, and we look forward to working together to advance these shared goals.”

As an Industry Supporter, Pacira is helping to establish a strong, mutually beneficial relationship with the anesthesiology community, strengthen collaboration between physician anesthesiologists and industry, and add to the value the Society provides to patients and the public, while providing invaluable year-round support of ASA programs and priorities related to non-opioid alternatives and postsurgical care.

Through the program, Pacira is supporting ASA’s major events, including this year’s ANESTHESIOLOGY® annual meeting, with valuable educational resources to improve patient care.

“Pacira is pleased to support ASA and we look forward to collaborating in our efforts to improve patient outcomes through opioid-minimizing strategies,” said Dave Stack, CEO and Chairman of Pacira. “Our organizations share a common interest in advancing education and innovation for the anesthesia community and the patients we serve. We believe that working together, Pacira and the ASA can effect significant change in the best interest of patients.”

Launched in 2010, ASA’s Industry Supporter Program is limited to 10 organizations at any time. Participation is intended for companies who want to stand apart by showcasing high-level commitment to the education of physician anesthesiologists, the anesthesia care team and advancement of the specialty.

About the American Society of Anesthesiologists

Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research, and scientific professional society with more than 56,000 members organized to advance the medical practice of anesthesiology and secure its future. ASA is committed to ensuring anesthesiologists evaluate and supervise the medical care of all patients before, during, and after surgery. ASA members also lead the care of critically ill patients in intensive care units, as well as treat pain in both acute and chronic settings.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org. To learn more about how physician anesthesiologists help ensure patient safety, visit . Like ASA on , follow on Twitter.

About Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) has three commercial-stage products: EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. Pacira is also developing other innovative products to address debilitating conditions such as cardiac electrical storm, atrial fibrillation, chronic pain, and spasticity. To learn more about Pacira, visit .



Investor Contact:

Pacira:
Susan Mesco, (973) 451-4030
 

Media Contact:
ASA:
Theresa Hill (773) 330-5273
 

Pacira:
Amber Sears, (973) 254-3587
 
EN
12/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacira Biosciences Inc.

 PRESS RELEASE

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on September 3, 2025 to nine new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4...

 PRESS RELEASE

Pacira BioSciences Reports Second Quarter 2025 Financial Results

Pacira BioSciences Reports Second Quarter 2025 Financial Results -- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Total revenues of $181.1 m...

 PRESS RELEASE

Pacira to Report Second Quarter 2025 Financial Results on Tuesday Augu...

Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 BRISBANE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday August 5, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answ...

 PRESS RELEASE

Pacira BioSciences Announces Strategic Collaboration to Significantly ...

Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient access BRISBANE, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic collaboration1 with Johnson & Johnson MedTech to significantly expand the market reach of ZILRETTA® (triamcinolone acetonide extended-...

 PRESS RELEASE

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2025 to seven new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch